**Core Concept:** Bosentan is an oral medication used for the treatment of pulmonary arterial hypertension (PAH), a group of disorders characterized by elevated pulmonary artery pressure and increased workload on the right ventricle of the heart. It is a dual endothelin receptor antagonist, inhibiting both endothelin-1 binding to its receptors and thereby reducing vasoconstriction and pulmonary vascular resistance.

**Why the Correct Answer is Right:** Bosentan acts as a competitive antagonist at both endothelin-1 type A (ETA) and endothelin-1 type B (ETB) receptors. By blocking these receptors, it prevents the binding of endothelin-1, a potent vasoconstrictor, to its receptors. This leads to reduced vasoconstriction and decreased pulmonary vascular resistance, ultimately improving the function of the right ventricle in patients with pulmonary arterial hypertension.

**Why Each Wrong Option is Incorrect:**

A. This statement is incorrect because bosentan does block endothelin receptors, which is its primary mode of action in the treatment of pulmonary arterial hypertension.

B. Although bosentan can be used in certain cases, it is not a first-line treatment for pulmonary arterial hypertension. The correct answer involves understanding the primary mode of action and clinical applications of bosentan.

C. Bosentan does interfere with nitric oxide synthesis, but this is not its primary mode of action in the treatment of pulmonary arterial hypertension. Bosentan's main mechanism relates to blocking endothelin receptors.

D. This statement is incorrect because the correct answer focuses on the primary mode of action and clinical application of bosentan, not its effect on other medications.

**Clinical Pearl:** Bosentan is a crucial medication in the treatment of pulmonary arterial hypertension, particularly for patients with World Health Organization (WHO) functional class III and IV symptoms. It is often used in combination with other therapies, like prostacyclin analogs or endothelin receptor antagonists, to improve overall outcomes in these patients.